Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices Delayed at least 15 minutes

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 23.15 - Change: 0.84 - Change %: 3.7651
05/24/2024 16:00:00 EST

Novocure Ltd (NVCR)

Industry: Medical Devices

Price Support Resistance

In the past 20 trading days, NVCR has been trading in a range between $24.05 and $12.24 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

NVCR is trading below resistance at $24.05, about 4% to the upside. There is support at $15.22 -34% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

Novocure Ltd $NVCR entered a Green zone 17 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $56.57, a potential upside of 153.56% from the recent price of 22.31. The stock is trading 270.42% (potential upside) below its 52 week high of $82.64 and 105.24 % (potential downside) above its 52 week low of $10.87 - based on the recent price.

Company Summary

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NVCR Website


TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routi.
Source: Business Wire
Thu, 23 May 2024 17:05:00 -0400
Sentiment: Neutral
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.
Source: InvestorPlace
Tue, 14 May 2024 07:08:00 -0400
Sentiment: Positive
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago.
Source: Zacks Investment Research
Thu, 02 May 2024 09:31:14 -0400
Sentiment: Negative
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocur.
Source: Business Wire
Thu, 02 May 2024 07:01:00 -0400
Sentiment: Neutral
Novocure Reports First Quarter 2024 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The first quarter was a period of strong execution,” said William Doyle, Novocure's Executive Chairman. “In Q1, GBM active patients grew 11%, we announced the METI.
Source: Business Wire
Thu, 02 May 2024 07:00:00 -0400
Sentiment: Neutral
Instituions Institution %: 84.96
Last QTR Institution change: 3443289

Insiders %: 9.259
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 9753
Insiders Net last QTR: -9753

Analyst Ratings
Target Price: 56.57
Overall Rating: 3.7143
Strong Buys (5): 2
Buys (4): 1
Holds (3): 4
Sells (2): 0
Strong Sells (1): 0

52 Week Hi: 82.64
52 Week Low: 10.87
Beta: 0.492
50 Day MA: 15.4152
200 Day MA: 16.0082

Earnings / Revenue Trends
Qtr Earnings Growth YOY: -0.06
Qtr Revenue Growth YOY: 0.134
Forward PE: 909.0909
Trailing PE: 0

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.